Physician profile
Scott Grant
NPI 1194762310
$1,856.30
in general payments reported to CMS, 2019-2025
15 companies · $404 in 2025
The $404 reported for 2025 was less than what a typical Retina Specialist provider received nationally (typical 2025 total: $460).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $239 · 2020: $242 · 2021: $112 · 2022: $105 · 2023: $547 · 2024: $207 · 2025: $404.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,137 · Education: $20.73.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,137.09 |
| Education | $20.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Apellis Pharmaceuticals, INC. | $411.69 | 2023-2025 | Syfovre |
| Abbvie INC. | $351.96 | 2022-2025 | |
| Carl Zeiss Meditec, INC. | $199.62 | 2020 | |
| Regeneron Healthcare Solutions, INC. | $179.72 | 2019-2024 | Eylea, Eylea Hd |
| Eyepoint US, INC. | $136.56 | 2021-2023 | |
| Alimera Sciences, INC. | $117.29 | 2021-2024 | Iluvien, Yutiq |
| Genentech USA, INC. | $116.27 | 2019-2025 | Vabysmo |
| Allergan, INC. | $115.08 | 2019-2020 | |
| Astellas Pharma US INC | $112.31 | 2023-2025 | Izervay |
| Coherus Oncology, INC. | $24.47 | 2022 | |
| Biogen, INC. | $21.85 | 2023 | |
| Harrow Eye, LLC | $19.65 | 2025 | Iheezo |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Boston Scientific Corporation | $16.21 | 2024 | Wavewriter Alpha Prime 16 |
| Pfizer INC. | $14.22 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Grant listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.